Thomas Rouse

2 Patents

• US120604292024

  Method of Treating Type 1 Interferon (ifn)-mediated Disease Using a Subcutaneous Dosing Regimen Comprising Anifrolumab

  Astrazeneca AB

  0 cites
• US116361172023

  Content Selection Using Psychological Factor Vectors

  DALLAS LIMETREE, LLC

  0 cites